Hinge Health Inc. Class A Common Stock vs Moody's Corporation — how do they compare? Hinge Health Inc. Class A Common Stock trades at $103.96 (market cap $8.48B), while Moody's Corporation trades at $467 (market cap $80.38B). The key difference: Moody's Corporation is far larger — about 9.5× Hinge Health Inc. Class A Common Stock's market cap, and Moody's Corporation pays a 0.89% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Moody's Corporation for 133 Days on average.
| HNGE | MCO | |
|---|---|---|
Market Cap | $8.48B | $80.38B |
Volume | 879,799 | 628,586 |
Sector | Health | Financials |
52-Week High | $105.14 | $539.61 |
52-Week Low | $31.17 | $412.23 |
Typical Hold Time | 0 Days | 133 Days |
Enterprise Value | $8.10B | $86.40B |
Dividend Yield | — | 0.89% |
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Moody's Corporation (MCO) trades at $462.77, down 1.64% on the day, as the stock consolidates near key support. The company maintains strong fundamentals with revenue reaching $7.72B in 2025 and net income margin expanding to 34.25%. Recent earnings beats and a bullish technical signal underscore positive momentum, while analyst consensus remains favorable with a $536.40 price target. Strategic moves like the PhilRatings stake and Google Cloud partnership highlight growth initiatives in the Asia-Pacific region and financial services technology.
Outlook: Moody's exhibits robust profitability and strategic expansion, supporting a positive investment case. Risks include high valuation multiples (P/E 29.45) and sensitivity to credit cycle fluctuations. The stock offers growth potential but requires monitoring of debt levels and macroeconomic trends affecting its credit rating business.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →